ClinicalTrials.gg

Program

irafamdastat

Also written as “BMS-986368”, “Irafamdastat” and “[14C]-BMS-986368”.

Its studies are mostly in Muscle Spasticity · Alzheimer Disease, led by Bristol-Myers Squibb.

Furthest: phase 2, since Jan 15, 20258 company-led studies, 4 open or runningNext primary completion: Dec 19, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb84 open or runningphase 2since Jan 15, 2025Sep 9, 2021Dec 19, 2026phase 1 · NCT07837115
  • Named in Bristol-Myers Squibb’s own pipeline as irafamdastat, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT05099822 · 84 enrolled · Belgium
  2. Dec 6, 2023Phase 1 study in Healthy ParticipantsNCT06170723 · 32 enrolled · United States
  3. Jan 19, 2024Phase 1 study in Healthy VolunteersNCT06227975 · 8 enrolled · United States
  4. Apr 29, 2024Phase 1 study in Healthy ParticipantsNCT06411730 · 56 enrolled · United States
  5. Jan 15, 20252 phase 2 studiesNCT06782490, NCT06808984
  6. Jul 9, 2026Phase 1 study in Healthy VolunteersNCT07700329 · 16 planned
  7. Sep 16, 2026Phase 1 study in Healthy VolunteersNCT07837115 · 24 planned · United States

Ahead

  1. Dec 19, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07837115
  2. Feb 23, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07700329
  3. May 26, 2027Primary completion: phase 2 study in Muscle SpasticityNCT06782490
  4. Nov 26, 2027Primary completion: phase 2 study in Psychomotor AgitationNCT06808984

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07837115Healthy Volunteers · United States1RecruitingDec 19, 202624
NCT07700329Healthy Volunteers1Not yet recruitingFeb 23, 202716
NCT06808984Psychomotor Agitation · United States, Argentina, Australia and more2RecruitingNov 26, 2027120
NCT06782490Muscle Spasticity · United States, Australia, Canada and more2RecruitingMay 26, 2027200
NCT06411730Healthy Participants · United States1CompletedOct 28, 202456
NCT06227975Healthy Volunteers · United States1CompletedApr 3, 20248
NCT06170723Healthy Participants · United States1CompletedMay 25, 202432
NCT05099822Healthy Volunteers · Belgium1TerminatedJul 11, 202284

How it is read

Names in the registry

  • “BMS-986368”, 5 entries
  • “Irafamdastat”, 1 entry
  • “[14C]-BMS-986368”, 1 entry
  • “CC-97489”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.